Navigation Links
Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

Recent Lassa fever outbreaks in Africa show vital need for new products that can be processed in any clinical or field lab

DENVER and NEW ORLEANS, May 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an extension of the collaborative effort for developing test kits for the detection of viral hemorrhagic fever (VHF).

The National Institutes of Health (NIH) has awarded a five-year grant to Tulane University for further development of the VHF kits. Collaborating with Corgenix and Tulane in this grant are Autoimmune Technologies, LLC, Vybion, Inc. and various partners in West Africa.

"We are extremely pleased to be part of this collaboration and to have received the NIH grant," said Douglass Simpson, Corgenix President and CEO. "We have made major strides in the development and clinical study phases and this will enable us to further develop the assays, complete the clinical studies and achieve full commercialization."

This is the second grant awarded to Tulane for Lassa virus products. Under the original grant awarded in 2005, the group developed and patented new recombinant proteins for Lassa virus and developed several viral detection products which were deployed in Africa for clinical testing. Under the new grant, Corgenix and the other partners will move the prototype Lassa products into full commercialization. Current tests typically require the culture of live Lassa virus in a high-containment laboratory to produce reagents. These tests are expensive, laborious to produce, and not commercially available, leaving no adequate options for laboratory diagnosis of VHFs in sub-Saharan Africa where most VHFs are endemic.

Joseph Fair, Ph.D., MPH, Director, Global Field Operations, Global Viral Forecasting Initiative, San Francisco, a consultant to the Lassa group, noted, "these recombinant-based serological assays designed for field deployment offer the public health and scientific communities a powerful tool to accurately assess the true disease burden and risks posed by Lassa and other especially dangerous pathogens, while collaterally improving upon their treatment and ultimately prevention."

Lassa fever, a serious viral disease spread by contact with infected rodents, is estimated to infect 300,000 to 500,000 people per year across West Africa, with approximately 5,000 deaths. In some areas of Sierra Leone and Liberia, up to 16 percent of people admitted to hospitals have Lassa fever. Lassa fever is also associated with occasional epidemics, during which the case-fatality rate can reach 50 percent.

New outbreaks of the Lassa fever have been reported recently, including in Nigeria. Daniel Bausch, M.D., MPH&TM, Director of Tulane's Research and Training Program in West Africa, observed, "We are now seeing much broader presence of this disease in Africa. Within the past year alone we have seen a significant increase in the number of cases in Nigeria, with increased fatalities. It is critical that the assays we have already developed and are using in Africa, as well as others still in our development pipeline, become fully deployed to aid in this vital effort."

Under the NIH grant, Tulane will conduct a five-year study designed to complete the tests for VHFs, some of which are potential bioterrorism agents due to their high fatality rate and ease of transmission from person-to-person.

Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principle Investigator of the program, added, "We have been very pleased with the results of our development effort. The products have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the health care in that part of the world, but will also fill a critical gap in bioterrorism defense. Now, under the new NIH award, we will complete the development and move to commercialization of the Lassa fever detection products and expand our efforts across Africa."

Dr. Garry stated that the group intends to expand this program to address other important infectious agents--such as Ebola, Marburg and other hemorrhagic fever viruses--that are of concern to the public health and bioterrorism preparedness communities.

About Corgenix Medical Corporation

Corgenix (Denver, Colo.) is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at

About Tulane University

Tulane University (New Orleans, La.) was founded in 1834. Tulane is one of the most highly regarded and selective research universities in the United States, and is a member of the prestigious Association of American Universities. Tulane's schools and colleges offer undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.

About Autoimmune Technologies, LLC

Autoimmune Technologies (New Orleans, La.) is a privately held biomedical company. It has licensed several breakthrough research discoveries from Tulane University School of Medicine and has made exciting discoveries of its own. Autoimmune is working to offer new diagnostic tests and new anti-viral therapeutics to the medical community based on this proprietary research.

About Vybion, Inc.

Vybion (Ithaca, N.Y.) is an emerging biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody selection and affinity maturation. The company's contract division has developed over 150 recombinant proteins in multiple expression systems including 12 biologic drugs in various phases of clinical development.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:11/24/2015)... 24, 2015 F1000Workspace - a ... since it was launched just six months ago. --> ... authoring platform for scientists - since it was launched just ... been loaded on to F1000Workspace - a research ... it was launched just six months ago. ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological ... in Chicago on Nov-29 th through ... st  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th ... will present its revolutionary whole body CZT digital SPECT/CT solution at ...
(Date:11/24/2015)... , Nov. 24, 2015 Teledyne DALSA , ... image sensing technology, will introduce its CMOS X-Ray detector ... , November 29 to December 3, at McCormick Place in ... detectors for diagnostic and interventional imaging will be on display ... family of advanced CMOS X-Ray detectors is the industry ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November ... determine which patients are or are not eligible for bariatric surgery. The article explains ... 40, are more than 100 pounds overweight, or have a BMI of 35 and ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
Breaking Medicine News(10 mins):